USA - New York Stock Exchange - NYSE:BAX - US0718131099 - Common Stock
The current stock price of BAX is 19.73 USD. In the past month the price increased by 0.98%. In the past year, price decreased by -39.9%.
ChartMill assigns a technical rating of 2 / 10 to BAX. When comparing the yearly performance of all stocks, BAX is a bad performer in the overall market: 84.1% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to BAX. While BAX is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months BAX reported a non-GAAP Earnings per Share(EPS) of 2.41. The EPS decreased by -19.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.62% | ||
| ROE | -4.71% | ||
| Debt/Equity | 1.21 |
25 analysts have analysed BAX and the average price target is 23.74 USD. This implies a price increase of 20.34% is expected in the next year compared to the current price of 19.73.
For the next year, analysts expect an EPS growth of -11.87% and a revenue growth 4.95% for BAX
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company is headquartered in Deerfield, Illinois and currently employs 38,000 full-time employees. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. The company provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
BAXTER INTERNATIONAL INC
One Baxter Parkway
Deerfield ILLINOIS 60015 US
CEO: Jose E. Almeida
Employees: 38000
Phone: 12249482000
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company is headquartered in Deerfield, Illinois and currently employs 38,000 full-time employees. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. The company provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
The current stock price of BAX is 19.73 USD. The price increased by 0.82% in the last trading session.
BAXTER INTERNATIONAL INC (BAX) has a dividend yield of 0.2%. The yearly dividend amount is currently 1.16.
BAX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BAX.
BAXTER INTERNATIONAL INC (BAX) has a market capitalization of 10.14B USD. This makes BAX a Large Cap stock.
The outstanding short interest for BAXTER INTERNATIONAL INC (BAX) is 6.67% of its float.